Personnel Moves Archives - Page 4 of 42

Cardiac Dimensions has a new chief medical officer

Satya Shreenivas. [Image courtesy of Cardiac Dimensions]Cardiac Dimensions announced today that it appointed Dr. Satya Shreenivas as its new chief medical officer (CMO).

Kirkland, Washington-based Cardiac Dimensions develops minimally invasive treatments for heart failure with functional mitral regurgitation (FMR). That includes the Carillon Mitral Contour System, for which the company has the ongoing EMPOWER trial. Its new CMO served as an advisor on that trial.

“I’ve seen the compelling clinical evidence on Carillon therapy from Europe and look forward to helping the team expand the supportive body of evidence for this intriguing technology with the U.S. pivotal EMPOWER trial,” said Shreenivas. “I have always been energized by my work with emerging technologies that fill an unmet clinical need and am excited by the opportunity this therapy presents to enhance the lives of heart failure patients in a way that isn’t possible today.”

More about the new CMO at C…

3M picks former NuVasive CEO as president of Medical Solutions

New 3M Medical Solutions President J. Christopher Barry. [Image from NuVasive]3M (NYSE: MMM) + announced that it named Chris Barry EVP and group president of its Medical Solutions Division.

Medical Solutions exists within the 3M Health Care business group. 3M expects to spin off its Health Care business in the first half of this year, after which point it will operate under the name “Solventum.”

Barry, the former CEO of NuVasive, is the latest in a string of high-profile appointments at the 3M unit. Bryan Hanson announced his departure from the corner office at Zimmer Biomet to take over the company in August. The company also landed former Insulet CFO Wayde McMillan as he takes over the same post.

The appointment of Barry goes into effect on March 1. 3M expects him to help drive profitable growth for the unit, which provides advanced wound care solutions.

Barry brings more than two decades of ex…

Medtronic brings back former VP as GM of Aortic unit

Simona Zannetti, GM of the Medtronic Aortic business unit. [Image from Simona Zannetti on LinkedIn]Medtronic (NYSE: MDT) + announced that it named Dr. Simona Zannetti as the GM of its Aortic business unit.

Zannetti previously spent 21 years at the medtech giant. She spent the last 16 months as SVP of clinical research at Penumbra, joining the interventional device maker in September 2022.

In a LinkedIn post today, Nina Goodheart, SVP and president, Structural Heart & Aortic at Medtronic, shared the news of Zannetti’s return.

“She is a familiar face to many of us and we’re so glad to have her back,” Goodheart wrote.

Among several roles at Medtronic over more than two decades, Zannetti most recently served as VP of clinical research and medical science for peripheral vascular health. She also had the post of VP of clinical research and the Office of Medical Affairs, Aortic, Peripheral and…

Orthofix has a new CFO as Massimo Caliafiore takes over as CEO

LimaCorporate CEO Massimo Calafiore

Orthofix Medical (Nasadaq: OFIX) + announced that it appointed a new CFO as its newly appointed CEO takes over the corner office.

The large orthopedic device maker appointed Julie Andrews as CFO as Massimo Calafiore assumes his position as CEO. Orthofix named Calafiore as its next CEO in November. However, the company had to wait until Enovis completed its acquisition of LimaCorporate for the appointment to go into effect. Calafiore served as Lima’s CEO until Enovis completed its acquisition last week.

Orthofix’s executive appointments come as part of a major shuffle at the top following the termination of three high-ranking executives. After the company began 2023 with a massive merger with SeaSpine, in September, it terminated a trio of executives with cause. The company cut ties with CEO Keith Valentine, CFO John Bostjancic and chief legal officer Patrick Keran followi…

SimBioSys wins FDA nod for TumorSight precision medicine platform

SimBioSys announced that it received FDA 510(k) clearance for its TumorSight cloud-based digital precision medicine platform.

FDA clearance came just days after the company inked a partnership with Mayo Clinic to develop precision medicine solutions.

The TumorSight platform takes a patient’s standard-of-care imaging to build a custom 3D model of their tumor. The tool provides 3D spatial visualizations of breast cancer to support more effective planning and consultations. SimBioSys said it gives clinicians and patients a more comprehensive understanding of their cancer and the potential options available.

Additionally, the TumorSight application provides insights like tumor volume, tumor-to-breast volume and tumor distance to key anatomical structures. It quantifies key metrics required in treatment planning.

SimBioSys also plans to expand the TumorSight platform and incorporate a suite of innovative tools. Those tools could extend to surgical plan…

Zimmer Biomet adds longtime orthopedic hospital leader to its board

Zimmer Biomet (NYSE: ZBH) + announced today that it appointed Louis A. Shapiro to its board of directors, effective immediately.

Shapiro previously served as president and CEO of the Hospital for Special Surgery (HSS). HSS, an academic center focused on musculoskeletal health, held the No. 1 ranking in U.S. orthopedic hospitals for 14 years in a row, as selected by U.S. News & World Report. It held the No. 1 spot in worldwide orthopedic hospitals ranked by Newsweek for the past four consecutive years.

He spent 17 years at HSS, joining as president and CEO in October 2006 before retiring in October 2023. Before joining HSS, Shapiro worked at Geisinger Health System from 2002 to 2006. There, he held a number of positions, ultimately serving as EVP and COO of the Clinical Enterprise.

Additionally, Shapiro served as a senior healthcare expert and consultant at McKinsey & Co. from 1999-2002. He held a number …

Stanford Biodesign co-founder joins Sofinnova Partners

Dr. Josh Makower [Image from his LinkedIn page]Sofinnova Partners — a prominent life sciences venture capital firm based in Paris, London, and Milan — has added Stanford Biodesign co-founder and director Dr. Joshua Makower as an advisory venture partner.

It’s been 23 years since Makower co-founded Stanford Biodesign alongside Dr. Paul Yock. They were instrumental in devising “The Biodesign Process” — used to teach students and industry leaders at Stanford and worldwide.

Makower is also the founder and executive chair of medical device incubator ExploraMed, which has launched 11 companies since 1995. His work has led to significant developments in the field — including the creation of NeoTract, maker of a device and procedure to treat an enlarged prostate; Acclarent, creator of devices for minimally invasive sinus surgeries; and TransVascular, which pioneered transvascular procedures. Teleflex, Johnson & Johnson, and Medtronic acquired the com…

Covalon Technologies names longtime 3M, BD exec as CEO

Covalon Technologies (TSXV:COV) announced today that it appointed Brent Ashton as its new CEO and as a board director.

Ashton’s appointment goes into effect immediately. The medtech industry veteran has experience leading large business units for wound care, vascular access, infection prevention and diagnostics. His track record includes time spent at large medtech companies like 3M and BD.

Covalon develops technologies and solutions for advanced wound care, infection prevention, and medical device coatings. The company believes that, with his broad experience, Ashton can lead the company into its next phase of growth and development.

Board Chair Amir Boloor has served as interim CEO since September when former CEO Brian Pedlar departed the corner office.

“On behalf of the board, I am delighted to welcome Mr. Brent Ashton to Covalon as its new CEO,” Boloor said. “Brent’s extensive medtech industry expertise specifically as it rel…

AtriCure adds J&J veteran to its board

New AtriCure board member Shlomi Nachman. [Image from J&J]AtriCure (Nasdaq:ATRC) announced today that it appointed longtime Johnson & Johnson executive Shlomi Nachman to its board of directors.

Nachman most recently served as company group chair within the Johnson & Johnson Medical Devices (now MedTech) business. He also joined the board of transcatheter aortic valve replacement technology developer JenaValve in September.

“I am thrilled that Shlomi has joined the board of directors,” said Michael Carrel, president and CEO of AtriCure. “He is one of the most well-respected leaders in the medical device space, having led Johnson & Johnson’s medical device business through a period of unprecedented growth. His experience in the AFib market will be invaluable as we continue our mission of healing the lives of those affected by this global epidemic.”

More about new AtriCure board member Shlomi Nachman

With more than 25 years in the medical devic…

BiVacor picks former BioVentrix CEO for its corner office

New CEO Jim Dillon. [Image courtesy of BiVacor]Artificial heart maker BiVacor announced today that it appointed Jim Dillon as its new CEO and as a member of its board.

Dillon, an experienced medical device executive, most recently served as CEO of BioVentrix, a heart failure treatment developer. His appointment follows last week’s naming of Axonics CEO Raymond W. Cohen as board chair at BiVacor.

“Jim’s leadership style, combined with his experience in building high-performance teams as well as expertise in the heart failure field, makes him the ideal person to lead BiVACOR,” Cohen said in a news release. “We are thrilled to have him join as CEO.”

Dillon’s experience includes developing cardiovascular therapies to enable native heart recovery and reduce the size of myocardial infarction. It also extends to repairing adult and congenital cardiac defects and volume management for congestive heart failure patients.

Prior to his time at BioVen…

BCI developer Synchron names new chief technology officer

Synchron Chief Technology Officer Riki Banerjee [Photo courtesy of Synchron]Synchron has promoted Riki Banerjee to chief technology officer, replacing co-founder Nick Opie in the role.

Opie will remain on the brain-computer interface (BCI) developer’s board of directors, the company said today.

Banerjee joined Synchron as VP of R&D in September 2021 after 12 years with Medtronic’s neurovascular operating unit. She will now lead all of Synchron R&D activities, including advancing the company’s neuroprosthesis device for patients with severe paralysis.

“Riki has been an instrumental part of Synchron’s growth and has also been the driving force behind our product design,” Synchron CEO and co-founder Dr. Tom Oxley said in a news release. “She is a senior leader at the intersection of neuromodulation innovation, engineering, implantable medical devices and commercialization. Her expertise and leadership will be transfo…

Inspire Medical adds Intuitive CMO Dr. Myriam Curet to its board

Intuitive Surgical Chief Medical Officer Dr. Myriam Curet [Photo courtesy of Intuitive Surgical]Inspire Medical Systems (NYSE:INSP) announced today that it appointed Dr. Myriam J. Curet as an independent board director.

Curet’s appointment went into effect on Dec. 21, 2023. She currently serves as EVP and chief medical officer at surgical robotics pioneer Intuitive Surgical. Curet spoke to Medical Design & Outsourcing this year to explain the secret behind Intuitive’s surgical robotics success.

“We are excited to add Dr. Curet, a practicing, board-certified minimally invasive general surgeon with extensive business and executive leadership experience in the medical device industry to our board of directors,” said Tim Herbert, president and CEO of Inspire Medical Systems. “Dr. Curet brings significant experience in developing and commercializing scalable solutions for minimally invasive surgery and we look forward to her guidance, expertise and cont…